genetic testing

The investment banking firm forecast Fiscal Year 2021 revenues of $235.6 million, higher than the consensus Wall Street estimate of $178.4 million.

The report noted that savings from the lower payment rates were offset by increased spending on other tests, including genetic tests.

The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.

BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.

The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.

The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.

The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.

Illumina had sought to exclude the Harmony test from the US Market, while Ariosa had sought to overturn the jury verdict with a post-trial maneuver.

Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.